Publications by authors named "Shuanghong Yin"

6 Publications

  • Page 1 of 1

Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway.

Eur J Pharmacol 2021 Oct 29;908:174399. Epub 2021 Jul 29.

Foshan Maternal and Child Health Research Institute, South Medical University Affiliated Maternal & Child Health Hospital of Foshan, Foshan, 528000, China; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. Electronic address:

Vorinostat is a histone deacetylase inhibitor (HDACi) that was demonstrated in our previous study to inhibit the proliferation, migration, and invasion of cervical cancer cells by regulating the PI3K/Akt signaling pathway. However, the molecular mechanism of vorinostat in cervical cancer treatment remains to be further elucidated. A nude mouse xenograft model was established to analyze the antitumor effect of vorinostat in vivo. The combination of iTRAQ-based proteomics and parallel reaction monitoring (PRM) technology has proven to be an efficient and reliable method to identify potential targets for cancer chemotherapy. In this study, 254 differentially expressed proteins in vorinostat-treated cervical cancer cells, among which 180 were upregulated and 74 were downregulated, were identified by using an iTRAQ-based proteomic strategy. Subsequent bioinformatic and PRM analysis of these differentially expressed proteins indicated that UBE2C is a promising target of vorinostat in the inhibition of cervical cancer cell proliferation. We confirmed that the expression of endogenous UBE2C in cervical cancer cell lines was significantly higher than that in normal cervical epithelial cell lines. Additionally, we found that vorinostat downregulated the expression of UBE2C, SQSTM1/p62, N-cadherin, vimentin and upregulated E-cadherin in SiHa and HeLa cells. Our results also showed that vorinostat can downregulate the expression of SQSTM1/p62, N-cadherin, and vimentin during the treatment of cervical cancer cells by regulating UBE2C, while upregulating the expression of E-cadherin. In conclusion, vorinostat reverses epithelial-mesenchymal transition by targeting UBE2C and controls the proliferation of cervical cancer cells through the ubiquitination pathway. UBE2C can be used as a promising target for the development of vorinostat treatment strategies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2021.174399DOI Listing
October 2021

Nanoscale ZnO-based photosensitizers for photodynamic therapy.

Photodiagnosis Photodyn Ther 2020 Jun 25;30:101694. Epub 2020 Feb 25.

Institute of Nanomedicine and Biomaterials, School of Sports and Health Science, Tongren University, Tongren 554300, China; Institute of Cultural and Technological Industry Innovation of Tongren, Tongren 554300, China; Guizhou Provincical College-Based Key Lab for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi Medical University, Zunyi 563000, China. Electronic address:

Due to the ability to induce the generation of reactive oxygen species (ROS) under light irradiation, ZnO nanoparticles show great potential in photodynamic therapy (PDT). Photo-triggered ROS production by ZnO nanoparticles and the resulting phototoxicity are efficient in killing cancer cells. This review highlights the recent exciting progress on the nanoscale ZnO-based photosensitizers (PSs) for PDT. Both the semplice ZnO nanoparticles as the PSs and the various chemicals (organic PS, dopant, metal and chemotherapeutic drugs) modified ZnO nanoparticles as the PSs show good ROS generation efficiency. The productive rate of ROS, the wavelength of exciting lights, and the therapeutic effect can be altered by doping different chemicals into ZnO nanoparticles at will. Additionally, we give some outlook on the design and functionalization of next-generation ZnO nanoparticles for more effective anti-cancer applications.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2020.101694DOI Listing
June 2020

The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.

Microb Pathog 2017 Nov 12;112:148-155. Epub 2017 Sep 12.

College of Agroforestry Engineering and Planning (Cultural and Technological Industry Innovation Research Center), Tongren University, Tongren 554300, Guizhou, China.

Brucellosis is a globally distributed zoonotic disease that causes animal and human diseases. Although effective, the current Brucella vaccines (strain M5-90 or others) have several drawbacks. The first is their residual virulence for animals and humans and the second is their inability to differentiate natural infection from that caused by vaccination. In the present study, Brucella melitensis M5-90 manB mutant (M5-90ΔmanB) was generated to overcome these drawbacks. M5-90ΔmanB showed significantly reduced survival in macrophages and mice, and induced strong protective immunity in BALB/c mice. It elicited anti-Brucella-specific IgG1 and IgG2a subtype responses and induced the secretion of gamma interferon (IFN-γ) and interleukin-4(IL-4). Results of immune assays showed, M5-90ΔmanB immunization induced the secretion of IFN-γ in goats, and serum samples from goats inoculated with M5-90ΔmanB were negative by Bengal Plate Test (RBPT) and Standard Tube Agglutination Test (STAT). Further, the ManB antigen also allows serological assays differentiate infections caused by wild strains from infections by vaccination. These results show that M5-90ΔmanB is a suitable attenuated vaccine candidate against virulent Brucella melitensis 16 M (16 M) infection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.micpath.2017.09.016DOI Listing
November 2017

[Endothelial progenitor cells promote osteogenic differentiation of marrow stromal cells in a paracrine manner].

Zhonghua Yi Xue Za Zhi 2015 Apr;95(16):1253-7

Department of Hepatobiliary Surgery, First Affiliated Hospital, Medical College of Shihezi University, Shihezi 832000, China; Email:

Objective: To explore the mechanisms of endothelial progenitor cells (EPCs)on promoting osteogenic differentiation of marrow stromal cells (MSCs).

Methods: EPCs and MSCs were isolated and cultured successfully from C57BL/7 murine bone marrow by in vitro amplification. EPC-conditioned medium (CM) was extracted to detect the concentrations of vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGFβ1), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), stromal cell-derived factor 1 (SDF-1) and basic fibroblast growth factor (bFGF) by enzyme-linked immunosorbent assay (ELISA). After 14 days of induction, alizarin red staining was used to detect every group's calcium salt deposition. And analyses were conducted for the effects of above mentioned antibodies of cytokines on osteogenic differentiation of MSCs.

Results: Positive rates of EPCs were 79.3%, 79.5%, 76.4% for VEGFR2, CD34 and CD133 respectively, and EPCs could form tube-like structure on matrigel. EPCs secreted VEGF, TGFβ1, PDGF, IGF-1, SDF-1 and bFGF. MSC/EPC group formed more mineralized nodules than MSC group, and semi-quantitative results showed the optical density of MSC/EPC group was higher than that of MSC group (0.733 ± 0.032 vs 0.236 ± 0.020, P < 0.001). The number of formed mineralized nodules of 50% EPC-CM group were more than those of 25% EPC-CM group, and semi-quantitative results showed that the optical density of 50% EPC-CM group was higher than that of 25% EPC-CM group (0.637 ± 0.028 vs 0.336 ± 0.024, P < 0.001), the number of formed mineralized nodules of 25% EPC-CM group were more than those of 0 EPC-CM group, and semi-quantitative results showed that the optical density of 25% EPC-CM group was higher than that of 0 EPC-CM group (0.336 ± 0.024 vs 0.239 ± 0.013, P = 0.004). On the basis of 50% of EPC-CM, the number of formed mineralized nodules significantly declined in the presence of anti-VEGF antibody, anti-TGFβ1 antibody, anti-IGF-1 antibody (P < 0.01).

Conclusion: EPCs promote osteogenic differentiation of MSCs probably through the paracrine effects of VEGF, TGFβ1 and IGF-1.
View Article and Find Full Text PDF

Download full-text PDF

Source
April 2015

A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection.

J Microbiol 2014 Aug 4;52(8):681-8. Epub 2014 Jul 4.

College of Animal Science and Technology, Shihezi University, Shihezi, 832003, P. R. China.

Brucellosis is a globally distributed zoonotic disease that causes animal and human diseases. However, the current Brucella abortus vaccines (S19 and RB51) are deficient; they can cause abortion in pregnant animals. Moreover, when the vaccine S19 is used, tests cannot differentiate natural from vaccinated infection. Therefore, a safer and more potent vaccine is needed. A Brucella abortus 2308 ery promoter mutant (Δery) was constructed to overcome these drawbacks. The growth of the Δery mutant was significantly attenuated in macrophages and mice and induced high protective immunity in mice. Moreover, Δery induced an anti-Brucella-specific IgG (immunoglobulin G) response and stimulated the expression of interferon-gamma (INF-γ) and interleukin-4 (IL-4). Furthermore, the expression of EryA antigen allowed for the serological differentiation between natural and vaccinated infection in mice. These results indicate that the Δery mutant is a potential attenuated live vaccine candidate against virulent Brucella abortus 2308 (S2308) infection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12275-014-3689-9DOI Listing
August 2014

A novel Omp25-binding peptide screened by phage display can inhibit Brucella abortus 2308 infection in vitro and in vivo.

J Med Microbiol 2014 Jun 10;63(Pt 6):780-787. Epub 2014 Apr 10.

College of Animal Science and Technology, Shihezi University, Shihezi 832003, PR China.

Brucellosis is a globally distributed zoonotic disease affecting animals and humans, and current antibiotic and vaccine strategies are not optimal. The surface-exposed protein Omp25 is involved in Brucella virulence and plays an important role in Brucella pathogenesis during infection, suggesting that Omp25 could be a useful target for selecting potential therapeutic molecules to inhibit Brucella pathogenesis. In this study, we identified, we believe for the first time, peptides that bind specifically to the Omp25 protein of pathogens, using a phage panning technique, After four rounds of panning, 42 plaques of eluted phages were subjected to pyrosequencing. Four phage clones that bound better than the other clones were selected following confirmation by ELISA and affinity constant determination. The peptides selected could significantly inhibit Brucella abortus 2308 (S2308) internalization and intracellular growth in RAW264.7 macrophages, and significantly induce secretion of TNF-α and IL-12 in peptide- and S2308-treated cells. Any observed peptide (OP11, OP27, OP35 or OP40) could significantly inhibit S2308 infection in BALB/c mice. Moreover, the peptide OP11 was the best candidate peptide for inhibiting S2308 infection in vitro and in vivo. These results suggest that peptide OP11 has potential for exploitation as a peptide drug in resisting S2308 infection.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1099/jmm.0.069559-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030397PMC
June 2014
-->